摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-(1'β,2'α,3'α,4'β)-1'-(6-amino-purin-9-yl)-2',3'-(dihydroxy)-4'-(N-hydroxy)amino-cyclopentane

中文名称
——
中文别名
——
英文名称
(+/-)-(1'β,2'α,3'α,4'β)-1'-(6-amino-purin-9-yl)-2',3'-(dihydroxy)-4'-(N-hydroxy)amino-cyclopentane
英文别名
(1R,2S,3R,5S)-3-(6-aminopurin-9-yl)-5-(hydroxyamino)cyclopentane-1,2-diol
(+/-)-(1'β,2'α,3'α,4'β)-1'-(6-amino-purin-9-yl)-2',3'-(dihydroxy)-4'-(N-hydroxy)amino-cyclopentane化学式
CAS
——
化学式
C10H14N6O3
mdl
——
分子量
266.26
InChiKey
ZKASVFXHAFQVAL-LAHCRNKXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    142
  • 氢给体数:
    5
  • 氢受体数:
    8

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (+/-)-(1'β,2'α,3'α,4'β)-1'-(6-amino-purin-9-yl)-2',3'-(dihydroxy)-4'-(N-hydroxy)amino-cyclopentane 在 palladium on activated charcoal 氢气 作用下, 反应 72.0h, 以94%的产率得到5'-amino-5'-deoxy-5'-noraristeromycin
    参考文献:
    名称:
    Synthesis of Novel Carbocyclic Adenosine Analogues as Inhibitors of Adenosine Kinase
    摘要:
    Several new 4'-amino substituted carbocyclic adenosine analogues (6, 7, 31) were prepared as potential inhibitors of the enzyme adenosine kinase. Three different heterocyclic base moieties (adenine, 8-azaadenine, and pyrazolo[3,4-d]pyrimidine) were incorporated into carbocyclic nucleoside analogues through the use of two different synthetic strategies. In both strategies, bicyclic isoxazolidine 9 (prepared through a hetero Diels-Alder reaction with cyclopentadiene) was used as the starting material. In one route, the N-O bond was reductively cleaved, and the hydroxyl group (after inversion and ring functionalization) was used as a leaving group to incorporate the heterocyclic base moiety as the key bond-forming step. A second, more efficient and higher yielding synthetic route was developed as a general solution to the synthesis of the target 4'-amino substituted carbocyclic adenosine analogues. In this methodology, the allylic C-O bond in the bicyclic isoxazolidine 9 was cleaved with double stereoinversion under palladium(0) catalysis as the key bond-forming step to stereospecifically incorporate the heterocyclic base moiety into the cyclopentane ring. The regioselectivity of key bond-forming steps was established principally by NMR methods, especially through (13)C NMR shifts and by NOE effects seen in the analogues, as well as by HMBC/HMQC experiments.
    DOI:
    10.1021/jo981658m
  • 作为产物:
    描述:
    5(R)-(6-amino-9H-purin-9-yl)-1(S),2(R)-dihydroxy-3(S)-N-(N-tert-butyloxycarbonylhydroxamino)cyclopentane 在 盐酸 作用下, 反应 4.0h, 以47%的产率得到(+/-)-(1'β,2'α,3'α,4'β)-1'-(6-amino-purin-9-yl)-2',3'-(dihydroxy)-4'-(N-hydroxy)amino-cyclopentane
    参考文献:
    名称:
    Synthesis of Novel Carbocyclic Adenosine Analogues as Inhibitors of Adenosine Kinase
    摘要:
    Several new 4'-amino substituted carbocyclic adenosine analogues (6, 7, 31) were prepared as potential inhibitors of the enzyme adenosine kinase. Three different heterocyclic base moieties (adenine, 8-azaadenine, and pyrazolo[3,4-d]pyrimidine) were incorporated into carbocyclic nucleoside analogues through the use of two different synthetic strategies. In both strategies, bicyclic isoxazolidine 9 (prepared through a hetero Diels-Alder reaction with cyclopentadiene) was used as the starting material. In one route, the N-O bond was reductively cleaved, and the hydroxyl group (after inversion and ring functionalization) was used as a leaving group to incorporate the heterocyclic base moiety as the key bond-forming step. A second, more efficient and higher yielding synthetic route was developed as a general solution to the synthesis of the target 4'-amino substituted carbocyclic adenosine analogues. In this methodology, the allylic C-O bond in the bicyclic isoxazolidine 9 was cleaved with double stereoinversion under palladium(0) catalysis as the key bond-forming step to stereospecifically incorporate the heterocyclic base moiety into the cyclopentane ring. The regioselectivity of key bond-forming steps was established principally by NMR methods, especially through (13)C NMR shifts and by NOE effects seen in the analogues, as well as by HMBC/HMQC experiments.
    DOI:
    10.1021/jo981658m
点击查看最新优质反应信息

文献信息

  • Synthesis of Novel Carbocyclic Adenosine Analogues as Inhibitors of Adenosine Kinase
    作者:Marlon Cowart、Michael J. Bennett、James F. Kerwin
    DOI:10.1021/jo981658m
    日期:1999.4.1
    Several new 4'-amino substituted carbocyclic adenosine analogues (6, 7, 31) were prepared as potential inhibitors of the enzyme adenosine kinase. Three different heterocyclic base moieties (adenine, 8-azaadenine, and pyrazolo[3,4-d]pyrimidine) were incorporated into carbocyclic nucleoside analogues through the use of two different synthetic strategies. In both strategies, bicyclic isoxazolidine 9 (prepared through a hetero Diels-Alder reaction with cyclopentadiene) was used as the starting material. In one route, the N-O bond was reductively cleaved, and the hydroxyl group (after inversion and ring functionalization) was used as a leaving group to incorporate the heterocyclic base moiety as the key bond-forming step. A second, more efficient and higher yielding synthetic route was developed as a general solution to the synthesis of the target 4'-amino substituted carbocyclic adenosine analogues. In this methodology, the allylic C-O bond in the bicyclic isoxazolidine 9 was cleaved with double stereoinversion under palladium(0) catalysis as the key bond-forming step to stereospecifically incorporate the heterocyclic base moiety into the cyclopentane ring. The regioselectivity of key bond-forming steps was established principally by NMR methods, especially through (13)C NMR shifts and by NOE effects seen in the analogues, as well as by HMBC/HMQC experiments.
查看更多

同类化合物

顺式5-氟-1-[2-(羟甲基)-1,3-氧硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮-13C,15N2 顺式5-氟-1-[2-(羟甲基)-1,3-氧硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮 顺-5-氟-1-[2-[[[[(((1,1-二甲基乙基)二甲基甲硅烷基]氧基]甲基]-1,3-氧杂硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮-13C,15N2 顺-5-氟-1-[2-[[[[(((1,1-二甲基乙基)二甲基甲硅烷基]氧基]甲基]-1,3-氧杂硫杂环戊-5-基]-2,4(1H,3H)-嘧啶二酮 阿巴卡韦羧酸盐 阿巴卡韦相关物质D 阿巴卡韦杂质F 阿巴卡韦杂质 阿巴卡韦中间体A5 阿巴卡韦5’-磷酸酯 阿巴卡韦,拉米夫定混合物 阿巴卡韦 芒霉素 艾夫他滨 腺苷基(3'-5')胞苷基(3'-5')胞苷游离酸 脱氧假尿苷 胸苷酰-(5'-3')-胸苷酰-(5'-3')-胸苷酰-(5'-3')-5'-胸苷酸 胰腺癌RX-3117 硫酸阿巴卡韦 甲基磷羧酸氢[(2S,5R)-5-(4-氨基-2-羰基嘧啶-1(2H)-基)-2,5-二氢呋喃-2-基]甲酯 瓶型酵母D 瓶型酵母A 环戊烯基尿嘧啶 水杨酸拉米呋啶 氟达拉滨EP杂质H 曲沙他滨 拉米夫定相关化合物(Α-TROXACITABINE) 拉米夫定杂质Ⅲ1-[(2R,5S)-2-羟甲基-1,3-氧硫杂环戊-5-基]-嘧啶-2,4(1H,3H)-酮 拉米夫定杂质1 拉米夫定S-氧化物(异构体混合物) 拉米夫定 拉米夫定 拉夫米定EP杂质J 拉夫米定EP杂质H 扎西他宾 恩替卡韦相关物质A 恩替卡韦一水合物 恩曲他滨杂质16 恩曲他滨S-氧化物 恩曲他滨 恩曲他滨 怀俄苷三乙酸酯 怀俄苷 己二酸,聚合1,2-丁二醇 外消旋拉米夫定酸 吡唑霉素 司他夫定 反式-阿巴卡韦盐酸盐 卡波啶 卡巴韦